Aurup, Peter
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChat
Most cited papers
- Verified
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet
Blood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes
Cited by 1,560
- Verified
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension
Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 392
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free